Residual immune activation and immunosenescence may contribute to chronic comorbidities in treated HIV-1 infection. It is unclear whether the integrase inhibitor, raltegravir (RAL), which has increased penetration into the gastrointestinal and lymphoid tissues, affects immunosenescence and T cell exhaustion to a greater extent than ritonavir boosted protease inhibitors (PIs).
A5260s is a substudy of a large prospective, randomized multicenter clinical trial that included HIV-1 infected treatment-naïve participants randomized to receive tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) plus: atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or RAL. Analyses include 234 participants (71% of all A5260s participants) who achieved and maintained plasma HIV-1 RNA <50 copies/ml by week 24. Blood cellular markers of immunosenescence and exhaustion of both CD4+ and CD8+ T cell subsets included: %CD28-CD57+, %CD28-CD57+ PD1+ and % PD1+. Changes from baseline were examined at earlier (24 weeks) and later (96 weeks) time points as fold change and 95% confidence intervals. Pairwise treatment group comparisons used Wilcoxon rank-sum tests with p-values adjusted with false discovery rate control.
Sustained declines over time were evident in all treatment groups for all CD4+ T cell markers of immunosenescence and exhaustion, with no apparent differences between treatment groups. Markers of CD8+ T cell exhaustion (but not immunosenescence) declined over time in all groups, without major differences between groups.
In this prospective randomized clinical trial of initially ART-naïve individuals initiating successful ART regimens of TDF/FTC with RAL, ATV/r or DRV/r, we did not find between groups differences in measured markers of T cell senescence or exhaustion after 96 weeks of ART. Despite successful ART therapy, markers of CD8+ T cell immunosenescence did not decrease by 96 weeks. These data support further the accumulating evidence of incomplete reversal of immune activation and senescence in the setting of current effective ART compared to ART naïve HIV-1 infected